Data from the SAPPHIRE study formed the basis of Scholar Rock's U.S. Food and Drug Administration request to approve apitegromab for SMA.

A decade on from a damning report into maternity services, its author says the "gross failure" that caused the death of a ...

Clinical research organisation (CRO) Icon has begun the integration of Medidata Clinical Data Studio into its clinical ...

Professor Karlo Malaga leads research focusing on pinpointing specific areas in the subthalamic region where deep brain ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

Medtronic’s VenaSeal Spectrum postmarket clinical trial program is highlighting the need for further patient-centric ...

The evolution of the safety and effectiveness evaluation of endovascular grafts intended for abdominal aortic aneurysm repair ...

A new study has revealed that more than half of the claims on TikTok about attention deficit hyperactivity disorder (ADHD) ...

“We found for acute low back pain, NSAIDs may be effective. For chronic low back pain, exercise, spinal manipulation, taping, ...

Ignota Labs is using AI to fix failed drugs and bring them to market. It raised $6.9 million from investors with this pitch ...

ICON Public Limited (NASDAQ:ICLR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the fifteen ...

Signs of neurological damage over time may not be needed for a diagnosis of MS in patients who strongly meet other criteria, ...